Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-014340
Filing Date
2024-11-05
Accepted
2024-11-05 08:31:31
Documents
48
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20240930x10q.htm   iXBRL 10-Q 1242201
2 EX-31.1 tmb-20240930xex31d1.htm EX-31.1 16863
3 EX-31.2 tmb-20240930xex31d2.htm EX-31.2 16242
4 EX-32.1 tmb-20240930xex32d1.htm EX-32.1 8285
5 EX-32.2 tmb-20240930xex32d2.htm EX-32.2 8847
  Complete submission text file 0001558370-24-014340.txt   4096810

Data Files

Seq Description Document Type Size
6 EX-101.SCH tmb-20240930.xsd EX-101.SCH 25782
7 EX-101.CAL tmb-20240930_cal.xml EX-101.CAL 18492
8 EX-101.DEF tmb-20240930_def.xml EX-101.DEF 95889
9 EX-101.LAB tmb-20240930_lab.xml EX-101.LAB 248989
10 EX-101.PRE tmb-20240930_pre.xml EX-101.PRE 182634
51 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20240930x10q_htm.xml XML 513441
Mailing Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024
Business Address 1 BRIDGE PLAZA, SUITE 275 FORT LEE NJ 07024 360-837-7232
Nuvectis Pharma, Inc. (Filer) CIK: 0001875558 (see all company filings)

EIN.: 862405608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41264 | Film No.: 241425878
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)